Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
Completed
GTx
Phase 3
2005-01-01
The purpose of this study is to determine if toremifene citrate is effective and safe in the
prevention of prostate cancer in men who have been diagnosed with high grade prostatic
intraepithelial neoplasia (PIN).
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Completed
GTx
Phase 3
2003-10-01
Androgen deprivation therapy (ADT) treatment for prostate cancer decreases the natural
hormone called testosterone. This type of therapy is very effective for the treatment of
prostate cancer. However, one of the side effects is bone loss or thinning of the bones that
can lead to osteoporosis and an increased risk of bone fractures (breaking of the bones). The
purpose of the study is to determine whether or not the addition of toremifene citrate (the
study drug) to therapy can prevent or decrease the number of bone fractures and to evaluate
its impact on side effects associated with testosterone reduction therapy.
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
Terminated
Japan Breast Cancer Research Network
Phase 2
2007-05-01
To investigate the benefit of postoperative adjuvant therapy using sequential administration
of the hormone, toremifene citrate (TOR) or anastrozole (ANA), after chemotherapy in breast
cancer.
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Withdrawn
Ipsen
Phase 3
2011-03-01
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing
the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation
Therapy.
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Withdrawn
GTx
Phase 3
2011-03-01
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing
the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation
Therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
